Founded in 1980, TCI Co., Ltd. transitioned from an Original Design Manufacturer (ODM) to a Contract Development and Manufacturing Organization (CDMO) in 2011 and went public in 2013. As of the end of 2023, the company employed 1,120 people. Leveraging our innovative product design and cutting-edge R&D technology, we develop unique, market-leading formulations and products tailored to our customers' needs.
Headquartered in Neihu Technology Park in Taipei, Taiwan, with operations across Asia and North America, TCI is committed to advancing economic, environmental, and social development, fostering sustainable value and long-term business potential.
TCI operates on the principle of Trust, with a focus on Creation and the strategic use of Intelligence. We are dedicated to a long-term commitment to delivering high-performance products and services to our clients and consumers.
Driven by consumer needs, we developed high-performance products using our exclusive IBD (Integrated Bioscience Design) methodology to "Join & Delight Consumers' Life!"
IBD (Integrated Bioscience Design) is a cross-disciplinary approach that combines expertise from fields such as chemistry, biology, mathematics, industrial engineering, genetic medicine, aesthetics, human factors, ergonomics, applied materials science, and consumer behavior research—all driven by consumer needs.
By exploring market demands such as anti-aging, environmental protection, postpartum recovery, and women's health, TCI creates high-performance products that improve consumers' lives through cutting-edge scientific research and technology. TCI has developed a wide range of products, including health foods, facial masks, functional drinks, collagen products, skincare products, and medical devices. Moving forward, we remain committed to our primary goal to Join & Delight Consumers' Life.
Strategy
TCI is at the forefront of innovation by focusing on consumer needs and significantly increasing investment in R&D. This approach allows us to establish industry-leading research capabilities and advanced manufacturing processes, empowering our customers’ brands to meet evolving consumer demands. By doing so, we create more effective and cost-competitive products, fulfilling our mission to “Join and Delight.”
Verification
At TCI, we prioritize R&D, academic partnerships, and substantial investment in capital and equipment. This enables us to clearly establish the link between product design and its effectiveness, ensuring optimal configurations that deliver high-performance products to consumers through our customers—aligned with our "Join and Delight" philosophy.
Partnership
By collaborating with corporate partners who share our vision, TCI fosters deeper interaction and cooperation across R&D, manufacturing, and global logistics. This is further enhanced by our complementary efforts in areas such as patent protection, intellectual property management, product certification, production line approvals, capital partnerships, and other intangible assets. Together, we build mutually protective partnerships that realize the shared value of "Join and Delight."
In 2021, TCI formally proposed the concept of creating an Integrated Bioscience Design Trading Company, starting the first year of mergers and acquisitions. The Group currently has several subsidiaries, including TCI, Shanghai BioTech Group, TCI Living, Quantum Biology, MBI, and PETFOOD. TCI will connect clients in different cities on a city-by-city basis and then link them with their industries to form a large, dense network. This network is our Integrated Bioscience Design Trading Company.
BioFunction, Shanghai BioTech Group. was established on September 1, 2011, headquartered in Shanghai, founder Yang William, chairman Lin Vincent, BioFunction is one of the subsidiaries of TCI,is a professional functional food OEM manufacturer. including liquid drink,liquid sachet, solid beverage, tablet, capsule.
Founded in 2019, TCI Living focuses on creating TCI's own brand to create the ideal life of the future by incorporating TCI's unique IBD raw materials into various types of products around the details of "clothing, food, housing and transportation". At present, we have AQUAGEN, Triple Probio and Dr.Q.
TCI GENE provides consumers with a complete solution for precision medicine, including preventive testing, disease treatment and postoperative care. Through precise genetic testing, we can gain a deeper understanding of the individual's constitution and combine it with precision medicine such as cell therapy, tissue engineering and human organs to create a long-lasting and healthy future.
Founded in 1998, MBI specializes in the research and development of natural biomaterials such as collagen, hyaluronic acid and bioceramics, and was acquired by TCI in 2021. Currently, 21 implantable medical devices and a number of ODM products are available in Taiwan, China, the United States, the European Union, Korea, Southeast Asia, Russia, and Ukraine.
We are committed to developing unique Integrated Bioscience Design materials. We explore natural resources around the world to find high-value materials and use automated bio-mining to explore the possibilities of various applications. After tens of thousands of scientific tests, and then clinically verified by humans, we have created high performance IBD materials.
With "We together, live happier" as the original intention, Pet Food has become the largest pet health food ODM in Taiwan, using human health food specifications to produce pet food.
We have many factory certifications and patents to create pet health food and snacks with functional ingredients and patented probiotics. We hope that owners can share food and health care products with their pets without any worries and live a happy and healthy life together.
For any further question, please feel free to contact us Email：tci-us@tci-bio.com
